LDS/Medical Tests/Cardio Pharmacogenetics (PGx) Gene Variation Panel

Cardio Pharmacogenetics (PGx) Gene Variation Panel

Metabolizing cardiovascular medication occurs via cytochromes produced in the liver. Because of the interindividual variability in metabolizing cardiovascular medication, the dosing of a certain medication can produce different results for patients. Part of this variability can be attributed to genetic factors that affect the activity of cytochromes, the rate of metabolizing medication, and ultimately the efficacy of the prescribed medication. Thus, using PGx testing determines a patient’s genetic makeup, as it pertains to drug metabolism, transportation, and utilization, and offers healthcare providers insight into a patient’s predicted response to a prescribed medication, and improve the precision of treatment.

Depending on laboratory panel design and patient population, Cardio Pharmacogenetics Gene Variation Panel might contain genes associated with few to many targets including ABCB1, ABCG2, APOE, CYP2C, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, F2, F5, ITGB3, MTHFR, SLCO1B1, VKORC1. PGx testing for cardiovascular medication provides genetic information that optimizes medication regimens for patients with heart disease. Healthcare providers can use PGx as a tool to better design a personalized treatment plan for their patients without having to take the trial-and-error approach, which can reduce the event of adverse drug reactions. Therefore, PGx enables safer, more effective, and cost-effective treatment by using genetic information that would help predict drug response, and further guide optimal drug and dose selection.

In addition, to above genes and variation the cardiology PGX panel will include genetic variation of coagulation factors FV, FII and MTHFR used for thrombotic genetic risk evaluation. The panel also includes APOE genetic variation testing for arteriosclerosis and cardiovascular disease and Alzheimer’s disease risk assessment. The genetic variations (mutations) of the above listed genes are tested using PCR based TaqMan® genotyping assay or next generation sequencing assay.

  • Evaluation of drug therapy used for cardiovascular diseases and disorders
  • Evaluation of thrombotic risk and thrombophilia related diseases
  • Evaluation of arteriosclerosis and cardiovascular disease risk assessment
Poor Metabolizer: Increased efficacy of active drug; active metabolite may accumulate; usually require lower dose to avoid toxic accumulation. Decreased efficacy of prodrug; prodrug may require lower dose to avoid toxic accumulation or require an alternate drug. Ultra-Rapid Metabolizer: Decreased efficacy of active drug; active metabolite rapidly inactivated usually require higher dose to offset inactivation. Increased efficacy of prodrug; rapid onset of effect, may require lower dose to prevent excessive accumulation of active metabolite. A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance.

See individual assay.

Multiplex Polymerase Chain Reaction (PCR) and allele-specific primer extension (ARMS), Next generation sequencing (NGS), Sanger sequencing.

Whole blood (EDTA), buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Supportive clinical tests, including chemistry, hematology, cardio markers, drug screening and confirmation.
1-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login